课题基金 / 基金详情

A5202: A PHASE III TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR

A5202: A PHASE III TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR
A5202:开放标签依非韦伦或阿扎那韦联合利托那韦的 III 期试验
批准号:
7607418
负责人:
PAUL SAX
金额:
$2.34万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-04-01 至 2008-03-31

项目摘要

项目成果

PAUL SAX的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to compare the effectiveness, safety, and tolerability of anti-HIV drug combinations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIV-1 DNA VRC-HIV 009-00 VP (GAG-POL-NEF_MULTICLADE ENV) IN HIV-1
  • 批准号:
    7719353
  • 项目类别:
  • 资助金额:
    $0.22万
  • 财政年份:
    2008
  • 负责人:
    PAUL SAX
  • 依托单位:
ALLRT: ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS
  • 批准号:
    7719367
  • 项目类别:
  • 资助金额:
    $0.33万
  • 财政年份:
    2008
  • 负责人:
    PAUL SAX
  • 依托单位:
A PHASE IV STUDY OF ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS
  • 批准号:
    7719352
  • 项目类别:
  • 资助金额:
    $0.07万
  • 财政年份:
    2008
  • 负责人:
    PAUL SAX
  • 依托单位:
THE SETPOINT STUDY: DOES EARLY THERAPY ALTER THE VIROLOGIC SETPOINT?
  • 批准号:
    7719364
  • 项目类别:
  • 资助金额:
    $0.11万
  • 财政年份:
    2008
  • 负责人:
    PAUL SAX
  • 依托单位:
海外基金